ProQR Therapeutics

81 articles with ProQR Therapeutics

• ProQR to Present at Upcoming JMP Securities Life Sciences Conference

  6/10/2021

  ProQR Therapeutics N.V., a company dedicated to changing lives through the creation of transformative RNA therapies for genetic eye diseases, announced that Company management will present during a fireside chat at the upcoming JMP Securities Life Sciences Conference.

• ProQR Announces First Quarter 2021 Operating and Financial Results

  5/6/2021

  Positive data reported from the Phase 1/2 clinical trial of QR-421a for the treatment of Usher syndrome and non-syndromic retinitis pigmentosa, with plans to advance the program into two pivotal Phase 2/3 trials before year end

• 

  BioSpace Global Roundup: Cevec Licenses AAV Program to Biogen

  1/14/2021

  Biopharma and life sciences companies from across the globe provide updates on their pipelines and businesses.
• 

  BioSpace Movers & Shakers, Oct. 9

  10/9/2020

  Biopharma and life sciences companies strengthen their leadership teams and boards with these Movers & Shakers.
• 

  BioSpace Global Roundup, April 2

  4/2/2020

  Biopharma companies from across the globe provide updates on their pipelines and business practices.
• 

  Clinical Catch-Up: December 9-13

  12/16/2019

  It was a particularly busy week in clinical trial news, largely because of the American Society of Hematology Annual Meeting. Here’s a look.
• 

  BioSpace Global Roundup, Dec. 12

  12/12/2019

  Companies from across the globe provide updates to their business and pipelines.

• ProQR Receives Orphan Drug Designation from FDA for QR-1123 for Autosomal Dominant Retinitis Pigmentosa

  11/21/2019

  ProQR Therapeutics N.V., a company dedicated to changing lives through the creation of transformative RNA medicines for severe genetic rare diseases, announced that it received Orphan Drug designation from the Food and Drug Administration for QR-1123.

• ProQR to Present at Upcoming Investor Conferences

  11/13/2019

  ProQR Therapeutics N.V., a company dedicated to changing lives through the creation of transformative RNA medicines for the treatment of severe genetic rare diseases, announced that Company management will present at upcoming investor conferences

• ProQR Announces Recent Progress and Financial Results for the Third Quarter of 2019

  11/6/2019

  Encouraging clinical data reported from Phase 1/2 trial of sepofarsen for LCA10

• ProQR Prices $50 Million Underwritten Public Offering of Ordinary Shares

  10/16/2019

  ProQR Therapeutics N.V. announced the pricing of its previously announced underwritten public offering of 9,090,909 ordinary shares at a price to the public of $5.50 per share.

• 

  Clinical Catch-Up: October 7-11

  10/14/2019

  It was a busy week for clinical trial announcements. Here’s a look.

• ProQR Announces Positive Top-Line Results from the Phase 1/2 Study of Sepofarsen in LCA10 Patients

  10/10/2019

  ProQR Therapeutics N.V. announced positive top-line results from the PQ-110-001 study, a Phase 1/2 dose range finding, first-in-human trial of sepofarsen (QR-110) in patients with Leber’s congenital amaurosis 10 (LCA10) due to the p.Cys998X mutation in the CEP290 gene.

• 

  BioSpace Movers and Shakers: Dec. 17

  12/17/2018

  With the year closing out, biotech and pharma companies are making adjustments to their leadership ranks and boards of directors.
• 

  Career Advice From a Scientist and Serial Entrepreneur

  12/11/2018

  Dinko Valerio offers wisdom garnered from a long career as a scientist, investor and entrepreneur.

• Ora®, Inc. has been retained by ProQR Therapeutics to provide mobility test services using the Ora-VNC™ for the QR-110 development program for Leber's Congenital Amaurosis Type 10

  11/13/2018

  ProQR Therapeutics announced positive interim results from the Phase 1/2 Clinical Trial of QR-110, a trial managed by Ora and featuring Ora's VNC™ mobility courses

• ProQR to Present Interim Phase 1/2 Results for QR-110 in Leber’s Congenital Amaurosis 10 at the Symposium for Retinal Degeneration on Sept. 5th

  8/15/2018

  Presentation at the 18th International Symposium on Retinal Degeneration (RD2018) at 8:30 am GMT on Sept. 5th

• ProQR Announces Financial Results for the Second Quarter of 2018

  8/8/2018

  Initiated WINGS, the first clinical trial to evaluate the safety and efficacy of QR-313 in patients that have recessive dystrophic epidermolysis bullosa (RDEB) due to mutations in exon 73 of the COL7A1 gene

• ProQR Initiates Phase 1/2 Clinical Trial of QR-313 for Dystrophic Epidermolysis Bullosa

  6/28/2018

  The trial, called WINGS, will evaluate the safety and efficacy of QR-313 in subjects with recessive dystrophic epidermolysis bullosa due to mutations in exon 73 of the COL7A1 gene.

• Foundation Fighting Blindness Will Provide Up to $7.5M in Funding to Develop Proqr’s Candidate QR-421a for Usher Syndrome Type 2A

  2/12/2018

  Foundation Fighting Blindness and ProQR enter into a partnership to develop QR-421a for Usher syndrome type 2A, targeting mutations in exon 13 of the causative USH2A gene.